Scholarlink

<p><i>Prevotella intermedia</i> is a gram-negative, anaerobic, multidrug-resistant bacterium known to cause oral infections. Given its clinical significance as an opportunistic pathogen, developing effective preventive and therapeutic measures is crucial. This study employed an integrated approach, combining subtractive proteomics and immunoinformatics, to identify novel therapeutic targets. We analyzed the core genome of <i>P. intermedia</i>, revealing five essential proteins as potential drug targets and three as potential candidates for a vaccine. The selected vaccine candidate proteins underwent additional evaluation to determine their immunogenic epitopes (B-cell, MHC-I, and MHC-II) and the design multi-epitope vaccine incorporating suitable linkers and adjuvants. Structural validation, including the identification of globular regions and post-translational modifications (PTMs), was performed. Molecular docking with the TLR4 receptor demonstrated strong interactions, and molecular dynamics (MD) simulations, dynamic cross-correlation matrix (DCCM) analysis, binding free energy calculations, and principal component analysis (PCA) confirmed stable binding between the vaccine prototypes and TLR4. Among the four proposed vaccines, we identified HBHA-PiMEV, L7/12-PiMEV, and GMCSF-PiMEV as most effective, with sustained interactions to human immune receptors and docking scores of −1110·2cal/mol, −1016·1 kcal/mol, and −1149·6 kcal/mol, as well as 15, 27, and 16 hydrogen bonds respectively. Based on different evaluation parameters, HBHA-PiMEV was identified as the most effective vaccine construct. Additionally, the novel drug targets were annotated for their roles in key biological processes, underscoring their therapeutic value. In summary, our investigation identified novel therapeutic targets and designed potent vaccine constructs against <i>P. intermedia</i> for further experimental validation to combat this multidrug-resistant pathogen.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Computational development of multi-epitope vaccine to induce adaptive immunity against multi-drug resistant Prevotella intermedia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月28日

查看全文
  • Ayesha Kanwal,
  • Mohibullah Shah,
  • Muhammad Umer Khan,
  • Muneeba Latif,
  • Hira Anum,
  • Sonia Younas,
  • Alanoud T. Aljasham,
  • Suvash Chandra Ojha

摘要

Prevotella intermedia is a gram-negative, anaerobic, multidrug-resistant bacterium known to cause oral infections. Given its clinical significance as an opportunistic pathogen, developing effective preventive and therapeutic measures is crucial. This study employed an integrated approach, combining subtractive proteomics and immunoinformatics, to identify novel therapeutic targets. We analyzed the core genome of P. intermedia, revealing five essential proteins as potential drug targets and three as potential candidates for a vaccine. The selected vaccine candidate proteins underwent additional evaluation to determine their immunogenic epitopes (B-cell, MHC-I, and MHC-II) and the design multi-epitope vaccine incorporating suitable linkers and adjuvants. Structural validation, including the identification of globular regions and post-translational modifications (PTMs), was performed. Molecular docking with the TLR4 receptor demonstrated strong interactions, and molecular dynamics (MD) simulations, dynamic cross-correlation matrix (DCCM) analysis, binding free energy calculations, and principal component analysis (PCA) confirmed stable binding between the vaccine prototypes and TLR4. Among the four proposed vaccines, we identified HBHA-PiMEV, L7/12-PiMEV, and GMCSF-PiMEV as most effective, with sustained interactions to human immune receptors and docking scores of −1110·2cal/mol, −1016·1 kcal/mol, and −1149·6 kcal/mol, as well as 15, 27, and 16 hydrogen bonds respectively. Based on different evaluation parameters, HBHA-PiMEV was identified as the most effective vaccine construct. Additionally, the novel drug targets were annotated for their roles in key biological processes, underscoring their therapeutic value. In summary, our investigation identified novel therapeutic targets and designed potent vaccine constructs against P. intermedia for further experimental validation to combat this multidrug-resistant pathogen.